Presentations – 5th CEE meeting

 

PRE-CONFERENCE - Wednesday, 18 September 

 
Logo_Liverpool_Course
 Khoo, Saye 2016 120x160Introductory lecture + questions
Saye Khoo, MD, PhD, University of Liverpool, United Kingdom
 

Fiona, Marra PhD

Mini Lecture - HIV/HCV coinfection
Fiona Marra, University of Liverpool, United Kingdom

 

 

Milosz Parczewski, MD, PhD

Case 1:  Multimorbidity + questions and discussion
Milosz Parczewski, MD, PhD, Pomeranian Medical University, Poland

 

 Anca Streinu-Cercel, MD, PhDCase 2:  Woman with HBV/HCV coinfection + questions and discussion
(No permission to publish slides or video)

Anca Streinu-Cercel, MD, PhD, Carol Davila University of Medicine and Pharmacy, Romania

 

Ales Chrdle photo (002)Case 3: From Chemsex to intensive care, then back to Chemsex? + questions and discussion
(Not yet available)
Aleš Chrdle, MD, České Budějovice Hospital, Czech Republic

 

 

 

MAIN PROGRAM

Day 1 - Thursday, 19 September 2019

 Session 1: Epidemiology of HIV and hepatitis in the CEE countries 
 

Milosz Parczewski, MD, PhD

Epidemiology of viral hepatitis infection and treatment in CEE countries
Milosz Parczewski, MD, PhD, Pomeranian Medical University, Sczecin, Poland

 

 
 Epidemiology of HIV infection and treatment in CEE countries
(Not yet available)
Anca Streinu-Cercel, MD, PhD, National Institute of Infectious Diseases Matei Bals, Romania
 
 Ivanova, Elena 2018Feasibility and acceptability of HCV self-testing
(Not yet available)

Elena Ivanova, MD, PhD, FIND (Foundation for Innovative New Diagnostics), Geneva, Switzerland
 
   
 Session 2: Access to care
 

EECA: Are we lagging behind?
Sergey Golovin, ITPCru, St. Petersburg, Russia

 
 

Access to quality assured  (WHO prequalified) generic medicines in the region
Liudmyla Maistat, Medicines Patent Pool, Geneva, Switzerland

 
 

Mojca Maticic, MD, PhDAccess to key populations
Mojca Maticic, MD, PhD, University of Ljubljana, Slovenia

 

 
 Round Table Discussion 
   
 Session 3: HIV and Hepatitis co-infection
 

Management of HIV/HCV co-infection in Young Women
Vadim Rassokhin, MD, 1st St. Petersburg State Medical University "Acad. I.P. Pavlov", St. Petersburg, Russia
(Presentation given by E. Boeva)

 
 Abstract-Driven Presentations 
 The prevalence of mutations of the Hepatitis C virus, associated with drug resistance to inhibitors of protein NS5A among patients of the republic of Belarus
Elena Gasich, Belarus
 #2
   
 Session 4: PrEP
 

PrEP and STI testing in CEE: What are the barriers, what works?
Milosz Parczewski, MD, PhD, Pomeranian Medical University, Sczecin, Poland

 

 
 Abstract-driven presentations 
 Persistence on HIV pre-exposure prophylaxis medication: A challenge in pre-exposure prophylaxis (PrEP) program in Georgia
(Not yet available)

Ekaterine Karkashadze, Georgia
 #3
 Virological efficacy of first-line regimens, resistance profile and factors influencing adherence to ART in clinical practice in Ukraine
Tetiana Kyrychenko, Ukraine
 #4
 Discussion 
   
 Industry-sponsored symposium 
   
 Session 5: Linkage to care and management of treatment failure in HIV
 

Switching to second line HIV therapy
Pavel Khaykin, MD, MainFachArzt, Frankfurt, Germany

 

 
 

Raben, DortheIntegrated testing for HIV, hepatitis, and STIs
Dorthe Raben, MSc, CHIP, Copenhagen, Denmark

 

 
 Discussion 
   
 

Day 2 - Friday, 20 September 2019

   
 Session 6: HIV and tuberculosis co-infection
 Management of TB and HIV infection
(Not yet available)

Daria Podlekareva, MD 
University of Copenhagen, Copenhagen, Denmark
 
 

The challenging TB case: clinical, virological and pharmacological considerations
(No permission to publish slides)
Jonathan Schapiro, MD, Sheba Medical Centre, Tel Aviv, Israel

 

 
 Discussion 
  Abstract-Driven Presentations 
 Epidemiology of HIV in the Baltic countries (Estonia, Latvia, Lithuania)
Saulius Čaplinskas, Lithuania
 #5
 Uptake and outcomes of dolutegravir based antiretroviral therapy in Georgia
(Not yet available)

Nino Rukhadze, Georgia
 #6
 The new tendencies in HIV and HCV epidemics in central region of Ukraine
Tetiana Koval, Ukraine
 #7
   
 Session 7: Abstract-driven presentations
 Management of Hepatitis C in primary healthcare in the country of Georgia
Akaki Abutidze, Georgia
 #8
 HCV prevalence and associated factors among people who inject drugs (PWID): Baseline results of Georgian PWID cohort study
Ketevan Shermadini, Georgia
 #9
 Diversity of HIV-1 subtypes in Russia 2009-2019
Konstantin Gromov, Russia
 #10
 Outcomes for hepatitis B vaccination among HIV-infected adults in Georgia
Shorena Dvali, Georgia
 #11
 Epidemiology of hepatitis B viral infection in the republic of Belarus
Viktar Mitsura, Belarus
 #12
 Implementation of the State Program on elimination of viral hepatitis C in Ukraine: achievements and challenges
Kristyna Pronyuk, Ukraine
 #13
 High level of integrase strand transfer inhibitors drug resistance mutations in INSTIs failed HIV-1 CRF06_cpx infected patients in Estonia
(No permission to publish slides)
Merit Pauskar
 #14
   
 Session 8: Hot topics in HIV and hepatitis
 Treatment of Hepatitis B in Ukraine: What are the remaining challenges?
(Not yet available)

Olga Golubovska, MD, PhD, Bogomolets National Medical University, Kyiv, Ukraine
 
 

Carolynne, Schwarze-Zander, MDVaccinations for HIV patients: which vaccinations when and how?Carolynne Schwarze-Zander, MD, University of Bonn, Bonn, Germany

 
 

Ligita JančorienėHIV/HCV Co-Infection: Influence on risk for cancer and cardiovascular events, and impact of successful HCV cure
Ligita Jancoriene, MD, PhD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania